Volume 4, Issue 3, September 2020, Page: 146-151
Role of the Ghanaian Clinical Pharmacist in Providing Evidence-based Pharmacotherapy for Heart Failure Patients: The Way Forward
Martin Mumuni Danaah Malick, Department of Pharmacy, School of Medicine and Health Sciences, University for Development Studies, Tamale, Ghana
Botah Baafi Adomako, Department of Pharmacy, Seventh Day Adventist Hospital, Tamale, Ghana
Kwame Agyepong, Department of Pharmacy, Tamale Teaching Hospital, Tamale, Ghana
Received: Jun. 21, 2020;       Accepted: Jul. 23, 2020;       Published: Aug. 20, 2020
DOI: 10.11648/j.ccr.20200403.20      View  110      Downloads  36
Abstract
Background: Heart failure is extensively characterized as a disorder arising from a complex interaction between impaired ventricular performance and neurohormonal activation. In order to achieve optimal therapeutic outcomes, all heart failure patients must be managed by a multidisciplinary team of healthcare providers, using evidence-based Pharmacotherapy. Purpose: The aim of this article is to assess the clinical role of the Ghanaian Pharmacists in optimizing Pharmacotherapy for heart failure patients based on internationally established clinical roles of Pharmacists. Methods: A literature search was conducted via google scholar using the “search engine” terms: Pharmacist, Clinical Role, Heart failure to look for all studies published in English. The search revealed a total of 98 studies. Only the studies that discussed the role of the clinical Pharmacists specific to heart failure or generally for patients with cardiovascular diseases were included; All other studies were excluded. A Total of 54 studies were used for data analysis. Clinical Pharmacists who are somehow involved in the management of heart failure patients were interviewed to ascertain their roles as members of a multidisciplinary team and their responses documented. Conclusions: A Multidisciplinary team approach including a Clinical Pharmacists with expertise in cardiovascular therapeutics, is required in the management of heart failure patients in order to improve therapeutic outcomes. The current clinical role of the Ghanaian Pharmacist in the management of heart failure patients is substandard.
Keywords
Heart Failure, Pharmacist, Clinical Role, Evidence-based Pharmacotherapy
To cite this article
Martin Mumuni Danaah Malick, Botah Baafi Adomako, Kwame Agyepong, Role of the Ghanaian Clinical Pharmacist in Providing Evidence-based Pharmacotherapy for Heart Failure Patients: The Way Forward, Cardiology and Cardiovascular Research. Vol. 4, No. 3, 2020, pp. 146-151. doi: 10.11648/j.ccr.20200403.20
Copyright
Copyright © 2020 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Parker, M. The neurohormonal hypothesis: A theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992; 20: 248-2254.
[2]
Takeda, A et al. Clinical services organization for heart failure. Cochrane database Syst Rev 2012; 9: CD002752.
[3]
Gattis, WA et al. Reduction in heart failure events by the addition of a clinical Pharmacist to the heart failure assessment recommendations and monitoring (PHARM) Study. Arch Inter Med. 1999; 159: 1939-1945.
[4]
Cooper, LB et al. Assessing the quality and comparative effectiveness of team-based care for heart failure: who, what, where and how? Heart Failure Clin. 2015; 11: 499-506.
[5]
Gunade, S et al. Development of a collaborative transition of care for heart failure patients. Am J Health Syst Pharm. 2015; 72: 1147–1152.
[6]
Martinez, AS et al. Implementation of a pharmacy managed heart failure medication titration clinic. Am J Health Syst Pharm. 2013; 70: 1070-1076.
[7]
Rodgers, JE et al. Underutilization of evidence-based therapies in heart failure: The Pharmacist Role: Pharmacotherapy 2007; 27 (4): 18-28.
[8]
Cheng, JN et al. Pharmacists role in the care of patients with heart failure: Review and future evolution. J Manag Care Pharm. 2014; 20: 206-213.
[9]
Stough, WG et al. Role and value of clinical Pharmacy in heart failure management. Clin. Pharmacol Ther. 2017; 102 (2): 209–212.
[10]
Helper, CD et al. Opportunities and responsibilities in Pharmaceutical care. Am J Hosp Pharm. 1990; 47: 533-541.
[11]
Helper, CD et al. Opportunities and responsibilities in Pharmaceutical care. Am Pharm. Educ. 1989; 53 (1): 7-15.
[12]
Strand, LM et al. Drug related problems: Their structure and function. DICP 1990; 24: 1093-1097.
[13]
Eggink RN, Lenderink AW, Widdershoven JW, van den Bemt PM. The effect of a clinical pharmacist discharge service on medication discrepancies in patients with heart failure. Pharm World Sci. 2010; 32 (6): 759-66.
[14]
Kripalani S, Roumie CL, Dalal AK, et al. Effect of a pharmacist intervention clinically important medication errors after hospital discharge: a randomized trial. Ann Intern Med. 2012; 157 (1): 1-10.
[15]
Jain A, Mills P, Nunn L, et al. Success of a multidisciplinary heart failure clinic for initiation and up-titration of key therapeutic agents. Eur J Heart Fail. 2005; 7 (3): 405-10.
[16]
Stewart S, Pearson S, Horowitz JD. Effects of a home-based intervention among patients with congestive heart failure discharged from acute hospital care. Arch Intern Med. 1998; 158 (10): 1067-72.
[17]
Stewart S, Vandenbroek AJ, Pearson S, Horowitz JD. Prolonged beneficial effects of a home-based intervention on unplanned readmissions and mortality among patients with congestive heart failure. Arch Intern Med. 1999; 159 (3): 257-61.
[18]
Rainville EC. Impact of pharmacist interventions on hospital readmissions for heart failure. Am J Health Syst Pharm. 1999; 56 (13): 1339-42.
[19]
Patel K, Sansgiry SS, Miller L. Pharmacist participation in home health heart failure programs. Am J Health Syst Pharm. 2003; 60 (21): 2259-60.
[20]
Varma S, McElnay JC, Hughes CM, Passmore AP, Varma M. Pharmaceutical care of patients with congestive heart failure: interventions and outcomes. Pharmacotherapy. 1999; 19 (7): 860-69.
[21]
Gattis WA, Hasselblad V, Whellan DJ, O’Connor CM. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. Arch Intern Med. 1999; 159 (16): 1939-45.
[22]
Whellan DJ, Gaulden L, Gattis WA, et al. The benefit of implementing a heart failure disease management program. Arch Intern Med. 2001; 161 (18): 2223-28.
[23]
Goodyer LI, Miskelly F, Milligan P. Does encouraging good compliance improve patients’ clinical condition in heart failure? Br J Clin Pract. 1995; 49 (4): 173-76.
[24]
Lowrie R, Mair FS, Greenlaw N, et al. Pharmacist intervention in primary care to improve outcomes in patients with left ventricular systolic dysfunction. Eur Heart J. 2012; 33 (3): 314-24.
[25]
Gwadry-Sridhar FH, Arnold JM, Zhang Y, Brown JE, Marchiori G, Guyatt G. Pilot study to determine the impact of a multidisciplinary educational intervention in patients hospitalized with heart failure. Am Heart J. 2005; 150 (5): 982.
[26]
López Cabezas C, et al. Randomized clinical trial of a post discharge pharmaceutical care program vs regular follow- up in patients with heart failure. Farm Hosp. 2006; 30 (6): 328-42.
[27]
Sadik, A et al. Pharmaceutical care for patients with heart failure. Br. J Clinical Pharmacol 2005; 60: 183-193.
[28]
Salas, CM et al. Implementing Pharmacy Practice resident run transition of care for heart failure patients: Effects on readmission rates. Am J Health Syst Pharm. 2015; 72 (11): 43-47.
[29]
Christensen, M et al. Medication review in hospitalized patients to reduce morbidity and mortality. Cochrane Database Syst Rev. 2013; 2: CD008986.
[30]
Gleason, KM, et al. Reconciliation of discrepancies in medication histories and admission orders of newly hospitalized patients. Am J Health Syst Pharm, 2004; 61: 1689–1695.
[31]
Bergkvist, A et al. Improved quality in the hospital discharge summary reduces medication errors. LIMM: Lansskrona Integrated Medicines Management. Eur J Clin Pharmacol 2009; 65: 1037–1046.
[32]
Hayes, BD, et al. Pharmacists conducted medication reconciliation in an emergency department. Am J Health Syst Pharm. 2007; 64: 1720-1723.
[33]
Murphy, EM, et al. Medication at an academic medical center: Implementation of a comprehensive program from admission to admission to discharge. Am J Health Syst Pharm. 2009; 66: 2126–2131.
[34]
Pippins, JR, et al. Classifying and predicting errors of inpatients medication reconciliation. J Gen Inter Med. 2008; 23: 1414-1422.
[35]
Steurbaut, S, et al. Medication history reconciliation by clinical pharmacists in elderly inpatients admitted from home or nursing home. DICP 2010; 44: 1596–1603.
[36]
Varkey, P, et al. Multidisciplinary approach to inpatients medication reconciliation in an academic setting. Am J Health Syst Pharm. 2007; 64: 850-854.
[37]
Gwadry-Sridhar, FH, et al. Pilot Study to determine the impact of a multidisciplinary educational intervention in patients hospitalized with heart failure. Am Heart J 2005; 150: 982: 1-9.
[38]
LaForest, S, et al. SERIOUS medication reconciliation clinic: improving transitions in care. J Card Fail. 2010; 16 (8): 112–116.
[39]
Boockvar, KS, et al. Medication reconciliation for reducing drug-discrepancy adverse events. Am J Geriatr Pharmacother. 2006; 4: 236–243.
[40]
Walker, PC, et al. Impact of Pharmacist -facilitated hospital discharge program: A quasi-experimental study. Arch Intern Med 2009; 169: 2003-2010.
[41]
Bertram, P, et al. The effect of S spironolactone on morbidity and mortality in patients with severe heart failure. N Eng J Med. 1999; 341: 709–717.
[42]
Cohn, JN, et al. A Randomized trial of angiotensin Receptor Blocker Valsartan in chronic heart failure. N Eng J Med. 2001; 345: 1667–1675.
[43]
Parker, MD, et al. Effect of carvedilol on survival in severe chronic heart failure. N Eng J Med 2001; 344: 1651–1658.
[44]
Beller, B, et al. Lisinopril versus placebo in the treatment of heart failure: The Lisinopril Heart failure study group. J Clin Pharmacol 1995; 35 (7): 673–680.
[45]
MacMurray, JJV, et al. Angiotensin – Neprilyn inhibition versus enalapril in heart failure. N ENG J Med 2014; 371: 993- 1004.
[46]
Luder, HR, et al. Transition care: Impact of community pharmacy post discharge medication therapy management on hospital readmission rates. J Am Pharm. Assoc. 2003; 2015 (55): 246–254.
[47]
Murray, MD, et al. Pharmacists interventions to improve medication adherence in heart failure. A Randomized trial. Ann Intern Med 2007; 146: 714–725.
Browse journals by subject